A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs SF 1126 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 12 Dec 2016 Status changed from not yet recruiting to recruiting.
- 11 Aug 2016 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 11 Aug 2016 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.